Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume 20, Issue 11, Pages 3225-3233Publisher
ELSEVIER SCIENCE INC
DOI: 10.1111/ajt.16079
Keywords
antibody biology; clinical research; practice; infection and infectious agents - viral; infectious disease
Categories
Funding
- National Institutes of Health [R01-HL105704]
- National Heart, Blood, and Lung Institute
- Charles and Helen Schwab Foundation
- Abbott Laboratories
Ask authors/readers for more resources
The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features, disease course, and serologic response of COVID-19 among immunosuppressed patients such as solid organ transplant (SOT) recipients, who are at presumed risk for more severe disease, are not well characterized. We describe our institutional experience with COVID-19 among 10 SOT patients, including the clinical presentation, treatment modalities, and outcomes of 7 renal transplant recipients, 1 liver transplant recipient, 1 heart transplant recipient, and 1 lung transplant recipient. In addition, we report the serologic response in SOT recipients, documenting a positive IgG response in all 7 hospitalized patients. We also review the existing literature on COVID-19 in SOT recipients to consolidate the current knowledge on COVID-19 in the SOT population for the transplant community.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available